Barclays PLC Invests $311,000 in Guardian Pharmacy Services, Inc. (NYSE:GRDN)

Barclays PLC acquired a new position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 18,500 shares of the company's stock, valued at approximately $311,000.

Several other institutional investors have also modified their holdings of the company. Wellington Management Group LLP purchased a new stake in shares of Guardian Pharmacy Services during the 3rd quarter worth $8,400,000. Point72 DIFC Ltd purchased a new stake in shares of Guardian Pharmacy Services during the 3rd quarter worth $573,000. Maven Securities LTD purchased a new stake in Guardian Pharmacy Services in the third quarter valued at $3,033,000. Foundry Partners LLC purchased a new stake in Guardian Pharmacy Services in the third quarter valued at $1,680,000. Finally, Royce & Associates LP purchased a new stake in Guardian Pharmacy Services in the third quarter valued at $1,260,000.

Insider Activity

In other news, Director Steven D. Cosler purchased 7,000 shares of the company's stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average cost of $21.22 per share, for a total transaction of $148,540.00. Following the completion of the purchase, the director now directly owns 17,713 shares in the company, valued at $375,869.86. The trade was a 65.34 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Guardian Pharmacy Services Stock Performance

Shares of NYSE:GRDN traded up $0.14 on Monday, reaching $20.53. The company's stock had a trading volume of 70,652 shares, compared to its average volume of 227,484. The business has a 50-day moving average price of $22.18. Guardian Pharmacy Services, Inc. has a 52-week low of $14.16 and a 52-week high of $25.74.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($2.00) EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($2.19). The firm had revenue of $314.39 million for the quarter, compared to analyst estimates of $303.21 million. As a group, research analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Stephens assumed coverage on shares of Guardian Pharmacy Services in a research report on Tuesday, October 22nd. They issued an "overweight" rating and a $21.00 price target for the company. Raymond James assumed coverage on shares of Guardian Pharmacy Services in a research report on Monday, October 21st. They issued an "outperform" rating and a $21.00 price target for the company. Finally, Truist Financial boosted their price target on shares of Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a "buy" rating in a research report on Friday, November 15th.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.